Particle Beam Therapy Versus Photon Radiotherapy for Extrahepatic Biliary Cancer-systemic Review and Meta-analysis

Overview

Journal J Radiat Res

Publisher Oxford University Press

Specialties Environmental Health
Oncology
Radiology

Date 2023 Apr 10

PMID 37036780

Authors

Hideya Yamazaki

Takuya Kimoto

Satoshi Teramukai

Kei Fujikawa

Kei Shibuya

Motohisa Suzuki

Kazuki Terashima

Takashi Iizumi

Masaru Wakatsuki

Osamu Suzuki

Takumi Fukumoto

Masayuki Ohtsuka

Affiliations

Soon will be listed here.

Abstract

Particle beam therapy (PT) is a potentially promising approach to the treatment of extrahepatic biliary cancer (EBC) because of its unique dose distribution using the Bragg peak. However, the superiority of PT to photon radiotherapy (XT) remains unclear. Therefore, we conducted a systematic review and meta-analysis to compare PT and XT for the treatment of EBC. The primary endpoint was overall survival (OS), which was pooled using a random-effects model. Nine articles comprising a total of 1558 patients (seven XT articles, n = 1488 patients; two PT articles, n = 70 patients) were screened. In addition, we compared the outcomes of XT and PT with the outcomes available from a prospective data registry (proton-net). The 1-year OS probability rates were 55, 65 and 72% for the XT group, PT group and PT registry, respectively. The 2-year OS probability rates were 26, 38 and 38% for the XT group, PT group and PT registry, respectively. The 3-year OS probability rates were 12, 35 and 18% for the XT group, PT group and PT registry, respectively. Although the difference between the 1-year OS rates of the XT group and PT registry was statistically significant, no other significant superiority was observed among these groups. In conclusion, the efficacy of PT was not superior to that of XT during this meta-analysis.

Citing Articles

A meta-analysis comparing efficacy and safety between proton beam therapy versus carbon ion radiotherapy.

Jang J, Kim K, Chen M, Akimoto T, Wang M, Kim M Cancer Med. 2024; 13(3):e7023.

PMID: 38396380 PMC: 10891363. DOI: 10.1002/cam4.7023.

References

Autorino R, Mattiucci G, Ardito F, Balducci M, Deodato F, Macchia G . Radiochemotherapy with Gemcitabine in Unresectable Extrahepatic Cholangiocarcinoma: Long-term Results of a Phase II Study. Anticancer Res. 2016; 36(2):737-40. View

Abe T, Shibuya K, Koyama Y, Okamoto M, Kiyohara H, Katoh H . Initial Results of Hypofractionated Carbon Ion Radiotherapy for Cholangiocarcinoma. Anticancer Res. 2016; 36(6):2955-60. View

Pollom E, Alagappan M, Park L, Whittemore A, Koong A, Chang D . Does radiotherapy still have a role in unresected biliary tract cancer?. Cancer Med. 2016; 6(1):129-141. PMC: 5269698. DOI: 10.1002/cam4.975. View

Yoshioka Y, Ogawa K, Oikawa H, Onishi H, Uchida N, Maebayashi T . Factors influencing survival outcome for radiotherapy for biliary tract cancer: a multicenter retrospective study. Radiother Oncol. 2014; 110(3):546-52. DOI: 10.1016/j.radonc.2014.01.003. View

Borenstein M, Hedges L, Higgins J, Rothstein H . A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2015; 1(2):97-111. DOI: 10.1002/jrsm.12. View

Kopek N, Holt M, Hansen A, Hoyer M . Stereotactic body radiotherapy for unresectable cholangiocarcinoma. Radiother Oncol. 2009; 94(1):47-52. DOI: 10.1016/j.radonc.2009.11.004. View

Nagino M, Hirano S, Yoshitomi H, Aoki T, Uesaka K, Unno M . Clinical practice guidelines for the management of biliary tract cancers 2019: The 3rd English edition. J Hepatobiliary Pancreat Sci. 2020; 28(1):26-54. DOI: 10.1002/jhbp.870. View

Brunner T, Blanck O, Lewitzki V, Abbasi-Senger N, Momm F, Riesterer O . Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma. Radiother Oncol. 2019; 132:42-47. DOI: 10.1016/j.radonc.2018.11.015. View

Kasuya G, Terashima K, Shibuya K, Toyama S, Ebner D, Tsuji H . Carbon-ion radiotherapy for cholangiocarcinoma: a multi-institutional study by and the Japan carbon-ion radiation oncology study group (J-CROS). Oncotarget. 2019; 10(43):4369-4379. PMC: 6633891. DOI: 10.18632/oncotarget.27028. View

10.

Tan Y, Zhu J, Qiu B, Xia N, Wang J . Percutaneous biliary stenting combined with radiotherapy as a treatment for unresectable hilar cholangiocarcinoma. Oncol Lett. 2015; 10(4):2537-2542. PMC: 4580044. DOI: 10.3892/ol.2015.3589. View

11.

Valle J, Wasan H, Palmer D, Cunningham D, Anthoney A, Maraveyas A . Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010; 362(14):1273-81. DOI: 10.1056/NEJMoa0908721. View

12.

Makita C, Nakamura T, Takada A, Takayama K, Suzuki M, Ishikawa Y . Clinical outcomes and toxicity of proton beam therapy for advanced cholangiocarcinoma. Radiat Oncol. 2014; 9:26. PMC: 3904195. DOI: 10.1186/1748-717X-9-26. View

13.

Lee J, Yoon W, Koom W, Rim C . Efficacy of stereotactic body radiotherapy for unresectable or recurrent cholangiocarcinoma: a meta-analysis and systematic review. Strahlenther Onkol. 2018; 195(2):93-102. DOI: 10.1007/s00066-018-1367-2. View

14.

Tao R, Krishnan S, Bhosale P, Javle M, Aloia T, Shroff R . Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis. J Clin Oncol. 2015; 34(3):219-26. PMC: 4980564. DOI: 10.1200/JCO.2015.61.3778. View

15.

Jethwa K, Sannapaneni S, Mullikin T, Harmsen W, Petersen M, Antharam P . Chemoradiotherapy for patients with locally advanced or unresectable extra-hepatic biliary cancer. J Gastrointest Oncol. 2021; 11(6):1408-1420. PMC: 7807283. DOI: 10.21037/jgo-20-245. View

16.

Shinchi H, Takao S, Nishida H, Aikou T . Length and quality of survival following external beam radiotherapy combined with expandable metallic stent for unresectable hilar cholangiocarcinoma. J Surg Oncol. 2000; 75(2):89-94. DOI: 10.1002/1096-9098(200010)75:2<89::aid-jso3>3.0.co;2-v. View

17.

Engineer R, Mehta S, Kalyani N, Chaudhari S, Dharia T, Shetty N . High dose chemoradiation for unresectable hilar cholangiocarcinomas using intensity modulated external beam radiotherapy: a single tertiary care centre experience. J Gastrointest Oncol. 2017; 8(1):180-186. PMC: 5334046. DOI: 10.21037/jgo.2017.01.20. View

18.

Torgeson A, Lloyd S, Boothe D, Cannon G, Garrido-Laguna I, Whisenant J . Chemoradiation Therapy for Unresected Extrahepatic Cholangiocarcinoma: A Propensity Score-Matched Analysis. Ann Surg Oncol. 2017; 24(13):4001-4008. DOI: 10.1245/s10434-017-6131-9. View

19.

Shinohara E, Mitra N, Guo M, Metz J . Radiotherapy is associated with improved survival in adjuvant and palliative treatment of extrahepatic cholangiocarcinomas. Int J Radiat Oncol Biol Phys. 2009; 74(4):1191-8. DOI: 10.1016/j.ijrobp.2008.09.017. View

20.

Elganainy D, Holliday E, Taniguchi C, Smith G, Shroff R, Javle M . Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma. Cancer Med. 2018; 7(10):4880-4892. PMC: 6198206. DOI: 10.1002/cam4.1734. View